What Are Neuropeptides and What Is Their Function?

Neuropeptides are small chains of amino acids that neurons use to communicate with each other and with cells throughout the body. They function as signaling molecules that regulate nearly every major aspect of physiology, from hunger and sleep to pain perception, stress responses, and immune defense. Unlike fast-acting neurotransmitters such as glutamate or GABA, neuropeptides work more slowly and over longer distances, acting as fine-tuners of brain activity rather than simple on-off switches. Hundreds of distinct neuropeptides have been identified, and their reach extends well beyond the brain into the gut, the immune system, and the bloodstream.

How Neuropeptides Are Built and Released

Neuropeptides start life as larger inactive proteins called precursors, which are assembled inside the neuron’s cell body. These precursors are then packaged into large dense-core vesicles, a type of storage compartment distinct from the smaller vesicles that hold conventional neurotransmitters. As the vesicles travel down the axon toward the nerve terminal, enzymes inside them clip the precursor into its active peptide fragments. A well-studied example involves the hypothalamic neurons that produce vasopressin and oxytocin: each is synthesized as a larger precursor containing additional protein segments called neurophysins, then sorted into dense-core vesicles and shipped to nerve terminals in the posterior pituitary for release into the bloodstream.¹

This manufacturing process takes time. Because the neuron has to transcribe a gene, build a precursor protein, package it, and transport it, replenishing a depleted neuropeptide supply is far slower than refilling the small-molecule transmitter pool. That difference has practical consequences: a neuron can run low on a neuropeptide during sustained activity, which limits how long the peptide signal lasts.

Volume Transmission and Why Distance Matters

Most people picture neural communication as a signal jumping neatly across a synapse from one neuron to the next. Neuropeptides often skip that tidy arrangement. Once released, many neuropeptides diffuse through the fluid surrounding brain tissue and act on receptors some distance away, a process sometimes called volume transmission. Experimental work using optical tools to track a released neuropeptide in living tissue found that the peptide could activate receptors at distances under roughly 130 micrometers within seconds, with response times climbing as the distance grew. Beyond about 220 micrometers, no detectable activation occurred at all, suggesting a natural limit on how far a single burst of peptide can reach.²

This mode of communication means a single neuropeptide release event can influence a cluster of neighboring cells rather than just the one cell across the synapse. It also means neuropeptide signaling is inherently fuzzier and longer-lasting than fast synaptic transmission, which is why these molecules are often described as modulators rather than transmitters in the strict sense.

Working Alongside Classical Neurotransmitters

Neuropeptides rarely work alone. In most neurons that produce them, they share space with a small-molecule transmitter like GABA, glutamate, or acetylcholine. When the neuron fires, both types of signal can be released, but often under different conditions. Low-frequency activity tends to release only the small-molecule transmitter from its small vesicles, while higher-frequency or burst firing is needed to mobilize the larger dense-core vesicles containing the neuropeptide. This co-transmission provides conjoint fast and slow signaling: the classical transmitter delivers a quick excitatory or inhibitory effect, while the neuropeptide adjusts the strength or duration of that effect over a longer timescale.³ In this way, neuropeptides can either amplify or dampen the signal their co-released partner delivers.⁴

The receptor side of the story reinforces this modulatory character. Neuropeptides primarily bind to a family of receptors called G protein-coupled receptors, which trigger slower intracellular cascading signals rather than the rapid ion-channel openings that classical transmitters use. Because only a handful of intracellular signaling cascades exist, the sheer variety of peptide-receptor pairings is thought to be what creates the complexity the brain needs.⁵

How the Signal Stops

If you are familiar with how serotonin or dopamine signaling ends, you might expect a reuptake pump to vacuum the neuropeptide back into the neuron. That is not what happens. Unlike most classical neurotransmitters, neuropeptides have no known reuptake system. Instead, their signals are terminated by enzymes in the surrounding tissue that chop the peptide into inactive fragments.⁶ Several membrane-bound peptidases have been identified in brain tissue, with endopeptidase-24.11 being one of the best-characterized. When researchers blocked this enzyme in rat brain slices, the amount of recoverable substance P (a pain-related neuropeptide) increased significantly, confirming the enzyme’s role in clearing that peptide under normal conditions.⁷

The reliance on enzymatic breakdown rather than reuptake has pharmacological implications. Drugs that target the reuptake machinery of serotonin or norepinephrine (like SSRIs or SNRIs) have no equivalent strategy for neuropeptides. Manipulating neuropeptide levels means either blocking the degrading enzymes or, more commonly, designing drugs that mimic or block the peptide at its receptor.

Appetite and Energy Balance

Some of the most dramatic demonstrations of neuropeptide function involve hunger and body weight. In a small region of the hypothalamus called the arcuate nucleus, two opposing populations of neurons use neuropeptides to regulate whether you feel hungry or full. Neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) signal hunger and stimulate food intake, while neurons expressing pro-opiomelanocortin (POMC) signal satiety and reduce food intake.⁸ NPY neurons also suppress energy expenditure, while POMC neurons increase it, so the two populations push metabolism in opposite directions.⁹

The relationship between these two neuron populations is not a simple seesaw. Research in mice on a high-fat diet has revealed that a subset of NPY neurons that lack AgRP can act on receptors expressed by POMC neurons, essentially hijacking the satiety system to drive further eating even when overall NPY levels have dropped. This circuit may help explain how obesity becomes self-reinforcing: under conditions of energy surplus, the appetite-promoting signal finds a back channel to keep food intake elevated.¹⁰

Pain Perception

Pain signaling relies heavily on neuropeptides at both the sending and receiving ends. Substance P is one of the primary neuropeptides released by pain-sensing nerve fibers in the spinal cord when you encounter a painful stimulus. It binds to NK1 receptors on downstream neurons, amplifying the pain signal being relayed to the brain. On the other side of the balance, endogenous opioid peptides (endorphins, enkephalins, dynorphins) act through mu- and delta-opioid receptors to suppress pain. Activation of these opioid receptors on primary pain-sensing fibers strongly reduces the release of substance P, essentially turning down the pain signal before it gets amplified.¹¹

Substance P itself has a surprisingly dual personality. When injected into the brain in very small amounts (a few nanograms), it actually produces pain relief, an effect that can be blocked by naloxone, suggesting it triggers endorphin release at low concentrations. At higher doses, that analgesic effect vanishes and substance P instead enhances pain sensitivity.¹² This dose-dependent flip is a good example of why neuropeptide biology is rarely straightforward: the same molecule can have opposing effects depending on how much of it is present and where.

Stress, Social Bonds, and Emotion

Oxytocin is probably the best-known neuropeptide in popular culture, often called the “bonding hormone.” The research behind that reputation is real, though more nuanced than headlines suggest. In prairie voles, a socially monogamous rodent species used widely in bonding research, oxytocin released within the hypothalamus proved both necessary and sufficient for social buffering of stress. When a stressed animal was paired with a familiar partner, hypothalamic oxytocin mediated the calming effect; blocking it eliminated the benefit of social contact.¹³

The flip side of bonding is loss. When monogamous prairie voles lose a partner, the oxytocin system appears to be compromised through multiple mechanisms, while a stress-related neuropeptide system involving corticotropin-releasing factor receptor 2 (CRFR2) becomes chronically active in the nucleus accumbens. Restoring oxytocin signaling in that brain region reversed the passive, depression-like coping behavior that followed partner loss.¹⁴ The interplay between oxytocin and the stress peptide CRF appears to be a two-way street, with each system regulating the other.¹⁵

Sleep and Wakefulness

The neuropeptides orexin A and orexin B (also called hypocretin 1 and 2) are produced by a small cluster of neurons in the lateral hypothalamus and serve as powerful promoters of wakefulness. Although they were originally discovered in the context of appetite research, their dominant role turned out to be sleep-wake regulation.¹⁶ When orexin-producing neurons are destroyed, the result is narcolepsy, a condition marked by uncontrollable bouts of sleep and sudden muscle weakness. This has been confirmed across species: genetic disruption of orexin signaling causes narcolepsy in mice, dogs, and humans.¹⁷

This discovery was a clinical breakthrough. Understanding that narcolepsy is fundamentally a neuropeptide-deficiency disease opened the door to targeted treatments. It also led, in the opposite direction, to the development of orexin receptor blockers (suvorexant, lemborexant) as sleeping pills, drugs that work by dampening the wake-promoting orexin signal rather than sedating the whole brain the way older sleep medications do.

Beyond the Brain

Neuropeptides are not confined to the nervous system. Substance P, for example, plays an active role in immune regulation. It mediates direct communication between nerve fibers and immune cells, influencing how fast immune cells proliferate and how much inflammatory signaling they produce. Some immune cells even secrete substance P themselves, suggesting the peptide is not merely a neural messenger that happens to reach immune tissue but is genuinely integrated into the immune response.¹⁸

In the gut, neuropeptides serve as a bridge between the microbiome and the rest of the body. Gut neuropeptides act as neuroimmune modulators mediating communication along the gut-brain axis, and recent work has found that some of these peptides also exert direct antimicrobial activity, giving them a dual role as both signaling molecules and first-line defenders against pathogens.¹⁹ Neuropeptides also regulate blood vessel tone in peripheral tissues. In porcine retinal arterioles, for instance, vasoactive intestinal peptide (VIP) and calcitonin gene-related peptide (CGRP) caused blood vessel dilation, while neuropeptide Y caused constriction, with both effects depending on the surrounding tissue being intact.²⁰

Neuropeptides in Disease

Disrupted neuropeptide signaling is implicated in a range of disorders beyond narcolepsy. In major depressive disorder, levels of the neuropeptide somatostatin drop in the cerebrospinal fluid, and expression tends to normalize when patients recover. The reduction appears linked to elevated cortisol and dysfunction in the body’s main stress hormone axis, and women show both a greater vulnerability to depression and a larger reduction in somatostatin levels in the cortex and amygdala compared with men.²¹ Similarly, postmortem studies of people who died by suicide while depressed have found reduced NPY messenger RNA and protein in the prefrontal cortex, alongside upregulation of NPY receptors, a pattern consistent with the brain trying to compensate for a peptide in short supply.²²

In age-related cognitive decline, neuropeptide abnormalities overlap with the hallmarks of Alzheimer’s disease. Measurements of somatostatin and NPY in the cerebrospinal fluid of elderly patients with mild cognitive impairment revealed correlations with amyloid-beta and tau proteins, the two molecular signatures of Alzheimer’s pathology.²³ Whether neuropeptide changes are a cause, a consequence, or an independent marker of neurodegeneration remains an active question, but these findings have encouraged interest in neuropeptide-based diagnostics and treatments.

Why Neuropeptide Drugs Are Hard to Make

Given how many diseases involve neuropeptide dysfunction, you might wonder why there are not more neuropeptide-based drugs. The main obstacle is delivery. Peptides are fragile molecules. They break down quickly in the bloodstream, get cleared by the liver, and struggle to cross the blood-brain barrier (BBB), the tightly sealed layer of cells that separates brain tissue from circulating blood.²⁴ The brain’s capillaries even have dedicated efflux pumps that actively push peptides back into the blood if they start to get through.²⁵

Researchers have tried various workarounds: attaching peptides to antibodies that hitch a ride on the brain’s own transport systems, coating peptides with sugar molecules to improve stability and uptake, and packaging them in nanocarriers designed to exploit existing BBB transport pathways.²⁵ Progress has been real but incremental, and for many brain-targeted neuropeptide therapies the delivery problem remains the bottleneck.

CGRP and Migraine as a Success Story

One area where neuropeptide-targeted drugs have broken through is migraine. Calcitonin gene-related peptide (CGRP) is released from trigeminal nerve fibers during a migraine attack and causes blood vessel dilation and inflammation in the meninges. Because CGRP acts largely outside the BBB in the trigeminovascular system, the delivery problem is less severe here. A class of small-molecule CGRP receptor blockers called gepants has proved effective for treating acute migraine attacks without causing the blood-vessel-constricting side effects that limit older drugs like triptans.²⁶

For prevention, monoclonal antibodies that either bind CGRP itself (eptinezumab, fremanezumab, galcanezumab) or block its receptor (erenumab) have reached the market. These antibodies reduce the number of headache days and improve disability scores, with tolerability that represents a substantial step forward from older preventive medications.²⁷ The migraine field is, in many ways, the proof of concept that targeting a single neuropeptide pathway can yield a practical, well-tolerated drug class.

An Ancient Signaling System

Neuropeptides are not a recent evolutionary invention layered on top of a more “basic” nervous system. They appear to be among the oldest signaling molecules in the animal kingdom. Neuropeptides and their G protein-coupled receptors are already abundant in cnidarians, the group that includes jellyfish, corals, and sea anemones, organisms with some of the most primitive nervous systems known.²⁸ Genomic analysis of hydrozoans (a subgroup of cnidarians) has confirmed that at least three neuropeptide families are shared across the group, consistent with these peptide systems originating very early in animal evolution.²⁹

In insects, neuropeptides orchestrate processes that have no counterpart in vertebrates. Molting, the periodic shedding and replacement of the exoskeleton, is controlled by a cascade of neuropeptides including ecdysis triggering hormone, eclosion hormone, and crustacean cardioactive peptide. These peptides must fire in precise sequence, and their correct timing is essential for the insect to survive each molt.³⁰ The ecdysis triggering hormone, synthesized by specialized peripheral cells rather than neurons, binds receptors on central nervous system neurons to kick off the whole process.³¹ The fact that neuropeptides run such different programs in insects and mammals yet share deep evolutionary roots underlines how versatile and fundamental this signaling toolkit is.